MEIP
Price
$2.70
Change
+$0.01 (+0.37%)
Updated
Jan 10, 04:59 PM (EDT)
Capitalization
17.99M
SAGE
Price
$5.55
Change
-$0.30 (-5.13%)
Updated
Jan 10, 04:59 PM (EDT)
Capitalization
357.86M
40 days until earnings call
Ad is loading...

MEIP vs SAGE

Header iconMEIP vs SAGE Comparison
Open Charts MEIP vs SAGEBanner chart's image
MEI Pharma
Price$2.70
Change+$0.01 (+0.37%)
Volume$100
Capitalization17.99M
Sage Therapeutics
Price$5.55
Change-$0.30 (-5.13%)
Volume$15.14K
Capitalization357.86M
MEIP vs SAGE Comparison Chart
Loading...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MEIP vs. SAGE commentary
Jan 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEIP is a Hold and SAGE is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 11, 2025
Stock price -- (MEIP: $2.69 vs. SAGE: $5.85)
Brand notoriety: MEIP and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MEIP: 54% vs. SAGE: 64%
Market capitalization -- MEIP: $17.92M vs. SAGE: $357.86M
MEIP [@Biotechnology] is valued at $17.92M. SAGE’s [@Biotechnology] market capitalization is $357.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $371.15B to $0. The average market capitalization across the [@Biotechnology] industry is $2.4B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MEIP’s FA Score shows that 0 FA rating(s) are green whileSAGE’s FA Score has 1 green FA rating(s).

  • MEIP’s FA Score: 0 green, 5 red.
  • SAGE’s FA Score: 1 green, 4 red.
According to our system of comparison, both MEIP and SAGE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEIP’s TA Score shows that 5 TA indicator(s) are bullish while SAGE’s TA Score has 6 bullish TA indicator(s).

  • MEIP’s TA Score: 5 bullish, 3 bearish.
  • SAGE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, SAGE is a better buy in the short-term than MEIP.

Price Growth

MEIP (@Biotechnology) experienced а +9.35% price change this week, while SAGE (@Biotechnology) price change was +7.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.93%. For the same industry, the average monthly price growth was -3.05%, and the average quarterly price growth was -1.61%.

Reported Earning Dates

MEIP is expected to report earnings on Aug 31, 2023.

SAGE is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (-4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SAGE($358M) has a higher market cap than MEIP($18M). MEIP YTD gains are higher at: 9.350 vs. SAGE (7.735). MEIP has higher annual earnings (EBITDA): -37.53M vs. SAGE (-371.15M). SAGE has more cash in the bank: 569M vs. MEIP (26.9M). SAGE has less debt than MEIP: SAGE (10.3M) vs MEIP (11.7M). SAGE has higher revenues than MEIP: SAGE (106M) vs MEIP (0).
MEIPSAGEMEIP / SAGE
Capitalization18M358M5%
EBITDA-37.53M-371.15M10%
Gain YTD9.3507.735121%
P/E Ratio1.09N/A-
Revenue0106M-
Total Cash26.9M569M5%
Total Debt11.7M10.3M114%
FUNDAMENTALS RATINGS
MEIP vs SAGE: Fundamental Ratings
MEIP
SAGE
OUTLOOK RATING
1..100
1725
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
7764
P/E GROWTH RATING
1..100
4397
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAGE's Valuation (25) in the Pharmaceuticals Other industry is somewhat better than the same rating for MEIP (59). This means that SAGE’s stock grew somewhat faster than MEIP’s over the last 12 months.

SAGE's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MEIP (100). This means that SAGE’s stock grew similarly to MEIP’s over the last 12 months.

SAGE's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as MEIP (98). This means that SAGE’s stock grew similarly to MEIP’s over the last 12 months.

SAGE's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as MEIP (77). This means that SAGE’s stock grew similarly to MEIP’s over the last 12 months.

MEIP's P/E Growth Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for SAGE (97). This means that MEIP’s stock grew somewhat faster than SAGE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEIPSAGE
RSI
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
79%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 8 days ago
73%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 23 days ago
81%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WDFC238.621.11
+0.47%
WD-40 Company
SBSI30.75N/A
N/A
Southside Bancshares Inc
XIN2.82-0.02
-0.70%
Xinyuan Real Estate Co Ltd
CE64.94-1.36
-2.05%
Celanese Corp
EOSE5.18-0.21
-3.90%
Eos Energy Enterprises

MEIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEIP has been loosely correlated with GOSS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MEIP jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEIP
1D Price
Change %
MEIP100%
+3.46%
GOSS - MEIP
45%
Loosely correlated
-5.41%
AXON - MEIP
28%
Poorly correlated
+2.72%
FBIO - MEIP
25%
Poorly correlated
-3.26%
ETON - MEIP
25%
Poorly correlated
+0.17%
SYRE - MEIP
25%
Poorly correlated
-1.36%
More